[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648614":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":28,"locations":34,"responsibleParty":50,"collaborators":54,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":10,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":87,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Gastrointestinal Tumour Network Zurich (GITZ)","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Trigger-positive participants",null,"Adults aged 60 years or older with at least one metabolic trigger (new-onset type 2 diabetes ≤24 months combined with unintentional weight loss \\>5% in 3 months) or familial\u002Fgenetic trigger (family history of PDAC or BRCA1\u002F2\u002FCDKN2A germline mutation), recruited through GP referral or self-presentation via study website.",[13],"Diagnostic Test: Structured case-finding pathway (MRI\u002FMRCP + PancreaSure biomarker assay)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Structured case-finding pathway (MRI\u002FMRCP + PancreaSure biomarker assay)","Single-visit structured pathway comprising: (1) standardised clinical risk assessment; (2) MRI\u002FMRCP with macrocyclic gadolinium contrast agent (Dotarem) per PRECEDE consensus protocol; (3) blood draw for blinded PancreaSure serum biomarker assay (Immunovia Inc.) and study biobank; (4) multidisciplinary tumour board review. No therapeutic intervention.",[9],[21,25],{"name":22,"affiliation":23,"role":24},"Jan Schmidt, Professor","Swiss Surgery, Klinik Im Park, Hirslanden, Zurich","STUDY_DIRECTOR",{"name":26,"affiliation":27,"role":24},"Alexander Siebenhüner, PD","Hirslanden Cancer Institute, Klinik Im Park, Zurich Role: Study Director",[29],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Saskia AD Hendrich, MD","CONTACT","+41 43 344 33 33","saskia.hendrich@ozh.ch",[35],{"facility":36,"status":10,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Onkozentrum Zürich AG","Zurich","Canton of Zurich","8038","Switzerland","CH",{"type":43,"coordinates":44},"Point",[45,46],8.55,47.36667,{"lat":46,"lon":45},[49],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Saskia Hendrich","Study Principal Investigator",[55,57],{"name":56,"class":6},"OnkoZentrum Zürich AG",{"name":58,"class":59},"Krebsliga Schweiz","UNKNOWN","100648614","structured-case-finding-for-pancreatic-ductal-adenocarcinoma-in-swiss-primary-care-a-feasibility-study-100648614",false,"NCT07723781","Structured Case-Finding for Pancreatic Ductal Adenocarcinoma in Swiss Primary Care: A Feasibility Study","PANCATCH-Pilot: Structured Early Detection of Pancreatic Ductal Adenocarcinoma in Swiss Primary Care - A Prospective Feasibility Study of a Case-Finding Pathway in the Canton of Zurich","PANCATCH-Pilot","Inclusion Criteria:\n\n* Age 60 years or older\n* Attendance at a participating GP practice in Canton Zurich or adjacent canton (maximum 1 hour travel time), or self-presentation via study microsite\n* At least one trigger criterion fulfilled: metabolic trigger (new-onset type 2 diabetes mellitus diagnosed within 24 months AND unintentional weight loss \\>5% body weight within 3 months) OR familial\u002Fgenetic trigger (≥2 first-degree relatives with PDAC, or ≥1 first-degree relative with PDAC, or BRCA1\u002F2 germline mutation, or CDKN2A mutation); combined with age ≥60 years\n* Written informed consent\n* Sufficient German or English language skills for study communication\n\nExclusion Criteria:\n\n* Prior or current diagnosis of pancreatic carcinoma or pre-malignant pancreatic lesion\n* Contraindication to MRI (metallic implants, severe claustrophobia without available alternative)\n* Active untreated psychiatric condition impairing capacity to consent\n* Pregnancy\n* Incapacity to provide informed consent",true,"ALL","60 Years",{"count":72,"type":73},50,"ESTIMATED","OBSERVATIONAL","Pancreatic ductal adenocarcinoma (PDAC) is diagnosed at an advanced, incurable stage in more than 80% of cases in Switzerland. Certain warning signs - new-onset diabetes, unexplained weight loss, or a family history of pancreatic cancer - may indicate elevated risk, but are not systematically assessed in primary care.\n\nPANCATCH-Pilot tests whether a structured case-finding pathway in Swiss general practices is feasible. Adults aged 60 years or older with one or more of these risk factors are invited to undergo an MRI\u002FMRCP examination of the pancreas and a blood draw for a blinded biomarker test (PancreaSure, Immunovia Inc.). Findings are reviewed by a multidisciplinary tumour board. The goal is not treatment, but to assess whether such a pathway works in the Swiss primary care context - as preparation for a larger national study.\n\nThe study enrolls 50 trigger-positive participants over 24 months through two parallel recruitment pathways: GP referral and self-presentation via a study website. Feasibility is assessed using six combined endpoints covering recruitment, process quality, safety, and equity.",[77,78],"Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)","Early Detection of Cancer",[80,81,82,83,84,85,86,40],"Pancreatic cancer","Case finding","Primary care","Feasibility study","MRI screening","PancreaSure","PDAC","NOT_YET_RECRUITING","2026-07-21",{"date":90,"type":91},"2026-07-23","ACTUAL",{"date":93,"type":73},"2026-10-01",{"date":95,"type":73},"2030-09-30",{"name":52,"class":6},1]